Piotr Wysocki

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  

Piotr Wysocki
Jul 26, 2024, 15:32 | Insight
Piotr Wysocki: Physical exercise - a new, promising neoadjuvant treatment modality in prostate cancer?
Piotr Wysocki recently posted on LinkedIn: “A study published in JAMA Oncology analyzed the impact and…
Jul 24, 2024, 03:52 | Insight
Piotr Wysocki: The type of immunotherapy-related adverse event impacts the outcomes of anti-cancer immunotherapy
Piotr Wysocki recently posted on LinkedIn: “Understanding the co-occurrence patterns of immune-related adverse events (irAEs) across…
Jul 21, 2024, 04:10 | OncoDaily Pulse
OncoDaily Party and Yvonne Award Photos - Part 1
On May 31st, 2024, during the ASCO Annual Meeting in Chicago, OncoDaily hosted the inaugural…
Jul 20, 2024, 17:44 | Insight
Piotr Wysocki: Who should not get dose-dense adjuvant chemotherapy in breast cancer?
Piotr Wysocki recently posted on LinkedIn: "For many years, dose-dense adjuvant chemotherapy has been considered the…
Jul 15, 2024, 11:19 | Insight
Piotr Wysocki: Does getting old decrease the risk of being diagnosed with lung cancer?
Piotr Wysocki recently posted on LinkedIn: “An intriguing article by Heidi Ledford has recently been published…
Jul 14, 2024, 01:25 | Insight
Piotr Wysocki: Nonrelapse mortality in CAR-T-treated patients. Beware of infections!
Piotr Wysocki recently posted on LinkedIn: "Cordas DM et al. conducted a systematic review and meta-analysis…
Jul 12, 2024, 16:05 | Insight
Piotr Wysocki: Bone Pain and Survival Among Patients With mHSPC
Piotr Wysocki recently posted on LinkedIn: "Bone pain is linked to worse overall survival (OS) in…
Jul 11, 2024, 09:55 | Insight
Piotr Wysocki: Tisotumab vedotin improves outcomes of patients with recurrent cervical cancer
Piotr Wysocki recently posted on LinkedIn: "Vergote I et al. published results of a phase III…
Jul 10, 2024, 12:12 | Insight
Piotr Wysocki: Active surveillance in patients at high risk of pancreatic cancer may significantly improve their outcomes
Piotr Wysocki recently posted on LinkedIn: "Blackford AL et al. published results of a cohort study…
Jul 9, 2024, 07:25 | Insight
Piotr Wysocki: Checkpoint inhibitor and TKI combinations in GU malignancies
Piotr Wysocki recently posted on LinkedIn: "A phase I study (Apolo AB et al. J Clin…
Jul 6, 2024, 06:30 | Blog
Oncoinfluencers to Follow on Social Media: Piotr Wysocki
Continuing our "Oncoinfluencers to Follow on Social Media" initiative at OncoDaily, we are pleased to feature…
Jul 4, 2024, 11:44 | Insight
Piotr Wysocki: 18F-PSMA-PET/CT beats multiparametric MRI in staging high-risk and intermediate-risk prostate cancers
Piotr Wysocki recently posted on LinkedIn: "Mookerji N et al. conducted a phase 2 prospective…
Jul 4, 2024, 08:30 | Insight
Piotr Wysocki: Cancer-related premature mortality decreases worldwide, especially in high-income countries, except for pancreatic cancer
Piotr Wysocki recently posted on LinkedIn: "The study by Murthy SS et al. (Lancet Oncology)…
Jul 3, 2024, 13:35 | OncoDaily Pulse
OncoDaily at ASCO 2024: OncoDaily Party, Yvonne Award and much more
OncoDaily at the Annual ASCO Conference 2024: A Comprehensive Report The American Society of Clinical…
Jul 2, 2024, 10:10 | Insight
Piotr Wysocki: Dendritic cell-based adjuvant therapy in pancreatic cancer
Piotr Wysocki recently posted on LinkedIn: "Freek R. van ‘t Land et al. published an interesting…
Jul 1, 2024, 23:51 | Insight
Piotr Wysocki: Neoadjuvant therapy for renal-cell cancer patients is still in its infancy, unlike in melanoma
Piotr Wysocki recently posted on LinkedIn: "The PROSPER ECOG-ACRIN EA8143 study (published online in Lancet…
Jun 29, 2024, 14:04 | Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 29, 2024, 05:21 | Insight
Piotr Wysocki: Adjuvant endocrine treatment in single and unemployed young breast cancer patients
Piotr Wysocki recently posted on LinkedIn: "The study by Julie A. Schmidt et al. published online in…
Jun 27, 2024, 09:01 | Insight
Piotr Wysocki: Anti-inflammatory drugs improve outcomes of patients with early PIK3CA-mutated colorectal cancer
Piotr Wysocki recently posted on LinkedIn: "For many years, anti-inflammatory drugs, mainly aspirin and celecoxib, have…
Jun 25, 2024, 14:07 | Insight
Piotr Wysocki: Minimally invasive surgery is out of the question in cervical cancer
Piotr Wysocki recently posted on LinkedIn: "Pedro Ramirez et al. published the results of the phase…
Jun 12, 2024, 15:34 | Insight
Piotr Wysocki: Dostarlimab combined with chemotherapy in dMMR/MSI-H advanced endometrial cancer patietns
Piotr Wysocki recently posted on LinkedIn: "Part 1 of the RUBY trial (NCT03981796) evaluated the…
Jun 12, 2024, 04:23 | Insight
Piotr Wysocki: Physicial exercise reduces the risk of recurrence - TNBC and HER2+/HR- breast cancer
Piotr Wysocki recently posted on LinkedIn: "Soldato D et al. conducted a multicenter prospective cohort analysis…
Jun 5, 2024, 15:22 | Insight
Piotr Wysocki: T-DXd in metastatic ER+/HER2-low breast cancer patients after endocrine treatment failure
Piotr Wysocki recently posted on LinkedIn: "Results of a Destiny-Breast06 trial have been presented by…
May 28, 2024, 13:25 | Blog
Piotr Wysocki: Does participation in clinical trials improve patients' outcomes?
Piotr Wysocki recently posted on LinkedIn: "Iskander R et al. conducted a systematic review and meta-analysis…
May 26, 2024, 06:54 | Positive
Yvonne Award Winners 2024 by OncoDaily
We are excited to announce the esteemed winners of the Yvonne Award 2024 by OncoDaily, designed…
May 24, 2024, 11:17 | Insight
Piotr Wysocki: Patients with hypermutated colorectal cancer (POLE/D1pd) derive profound benefit from immunotherapy
Piotr Wysocki recently posted on LinkedIn: "Ambrosini N et al. published online (Annals of Oncology) the…
May 17, 2024, 17:53 | Insight
Piotr Wysocki: Better responses to immunotherapy in NSCLC patients with rare EGFR mutation
Piotr Wysocki recently posted on LinkedIn: "The efficacy of immune checkpoint inhibitors (ICI) as monotherapy in…
May 17, 2024, 16:56 | Insight
Piotr Wysocki: Liver resection vs nonsurgical treatments in patients with early multinodular hepatocellular cancer
Piotr Wysocki recently posted on LinkedIn: "Current Barcelona Clinic Liver Cancer guidelines do not support…
May 17, 2024, 12:54 | Insight
Piotr Wysocki: Anti-HER2 treatment in patients with advanced biliary cancer
Piotr Wysocki recently posted on LinkedIn: "The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is…
May 14, 2024, 09:21 | Drugs
Piotr Wysocki: Pembrolizumab prevents recurrence in BCG-resistant bladder cancer
Piotr Wysocki recently posted on LinkedIn: "Necchi A et al. published a phase II single-arm study…
May 10, 2024, 17:49 | Drugs
Piotr Wysocki: Relatlimab does not improve the activity of nivolumab plus chemotherapy
Piotr Wysocki recently posted on LinkedIn: "RELATIVITY-060 was an open-label phase II study investigating the…
May 10, 2024, 10:27 | Opinion
Piotr Wysocki: FDG PET can predict response to immunotherapy in melanoma patients
Piotr Wysocki recently posted on LinkedIn: "Anderson TM et al. published the results of a study…
May 9, 2024, 06:45 | Insight
Piotr Wysocki: Neoadjuvant chemo-hormonal therapy before prostatectomy: First randomized study
Piotr Wysocki recently posted on LinkedIn: "Qian H et al. conducted a randomized clinical trial (phase…
May 8, 2024, 14:55 | Insight
Piotr Wysocki: 15-year colonoscopy interval is safe for individuals with no CRC history
Piotr Wysocki recently posted on LinkedIn: "A routine approach for individuals who had no negative…
May 8, 2024, 07:02 | Insight
Piotr Wysocki: Immunotherapy after chemotherapy may be the right choice
Piotr Wysocki recently shared on LinkedIn: "Mariniello A. et al. published results of an important preclinical…
May 6, 2024, 09:34 | Insight
Piotr Wysocki: Striking activity of metronomic chemotherapy in a critically advanced cutaneous squamous cell cancer
Piotr Wysocki recently shared on LinkedIn: "In many countries, the availability of checkpoint inhibitors-based immunotherapy is…
May 5, 2024, 12:04 | Blog
Piotr Wysocki: Elective Pelvic Lymph Node Radiation for elderly patients with prostate cancer
Piotr Wysocki recently shared on LinkedIn: "Sayan M et al. analyzed individual patient data from a…
May 5, 2024, 10:26 | Insight
Piotr Wysocki: Older age is a negative prognostic factor in endometrial cancer
Piotr Wysocki recently shared on LinkedIn: "Wakkerman FC et al. published in Lancet Oncology an…
May 4, 2024, 13:14 | Insight
Piotr Wysocki: Chronic stress increases the risk of cancer metastasis
Piotr Wysocki recently shared on LinkedIn: "A recent study published in Cancer Cell by Xue-Yan He,…
May 2, 2024, 09:39 | Insight
Piotr Wysocki: Combination of chemotherapy and endocrine treatment in breast cancer
Piotr Wysocki recently shared on LinkedIn: "Dear Colleagues, I invite you to read a review article…
May 1, 2024, 17:21 | Drugs
Piotr Wysocki: Adjuvant aspirin failed to improve outcomes of breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "A large, phase III trial (Alliance A011502) enrolled 3020…
May 1, 2024, 09:08 | Insight
Piotr Wysocki: Adjuvant immunotherapy in NSCLC patients who underwent radical resection preceded by immunotherapy
Piotr Wysocki recently shared on LinkedIn: "Zhou Y et al. have conducted an indirect meta-analysis…
May 1, 2024, 07:00 | Insight
Piotr Wysocki: Cannabis and cannabinoid in adult cancer patients
Piotr Wysocki recently shared on LinkedIn: "ASCO guidelines devoted to cannabis and cannabinoid use in adult…
Apr 28, 2024, 17:10 | Blog
Piotr Wysocki: Metronomic Chemotherapy in Cancer Treatment - Call for Papers
Piotr Wysocki recently shared on LinkedIn: "Dear Colleagues, As a Guest Editor, I invite you to…
Apr 28, 2024, 12:38 | Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 26, 2024, 20:41 | Insight
Piotr Wysocki: CAR-T therapy seems to be associated with second primary malignant neoplasms
Piotr Wysocki recently shared on LinkedIn: "In a research letter published online in JAMA Oncology,…
Apr 26, 2024, 17:55 | Insight
Piotr Wysocki: NECTIN4 amplification is a predictive factor for enfortumab vedotin efficacy
Piotr Wysocki recently shared on LinkedIn: "Kluemper et al. published results of a study evaluating NECTIN4…
Apr 25, 2024, 21:09 | Insight
Piotr Wysocki: Salvage re-irradiation is a feasible option in locally recurrent prostate cancer after primary curative radiotherapy
Piotr Wysocki recently shared on LinkedIn: "Locally recurrent prostate cancer (PC) in patients who underwent primary…
Apr 25, 2024, 21:06 | Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Apr 25, 2024, 12:40 | Drugs
Piotr Wysocki: Similar activity of topotecan and liposomal irinotecan in second-line treatment of SCLC
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 22, 2024, 18:48 | Insight
Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 22, 2024, 18:37 | Insight
Piotr Wysocki: Postpartum breast cancer in BRCA1/2-mutation carriers is associated with poor outcomes, especially in patients with BRCA1 mutations
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 20, 2024, 18:21 | Insight
Piotr Wysocki: Pregnancy and anticancer immunotherapy - How safe is accidental exposure to immune checkpoint inhibitors?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 19, 2024, 20:03 | Insight
Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients - underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 17, 2024, 18:37 | Blog
Piotr Wysocki: A new, broad-spectrum RAS-GTP inhibitor holds promise in pancreatic cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 16, 2024, 11:36 | Insight
Piotr Wysocki: Rechallenge with anti-EGFR antibodies is a feasible and safe strategy in refractory metastatic colorectal cancer patients with RAS/BRAFwt ctDNA
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 16, 2024, 11:25 | Drugs
Piotr Wysocki: Adjuvant olaparib improves outcomes of breast cancer patients with germinal BRCA1/2 mutations at the cost of slightly decreased quality of life
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 15, 2024, 14:41 | Drugs
Piotr Wysocki: The [177Lu]Lu-PSMA-617 plus enzalutamide combination is active and safe in mCRPC patients, but is it really an option for first-line treatment?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 14, 2024, 03:52 | Drugs
Piotr Wysocki: CLEAR trial – another study demonstrating that Immunotherapy and TKI combination should not be routinely recommended to favorable-risk RCC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 12:10 | Insight
Piotr Wysocki: Cetuximab monotherapy maintenance after FOLFIRI may not be the optimal choice but can be considered in selected mCRC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 11:46 | Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Apr 11, 2024, 15:23 | Drugs
Piotr Wysocki: Adagrasib and cetuximab in KRAS G12C-mutated colorectal cancer is a safe and active
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 10, 2024, 08:41 | Drugs
Piotr Wysocki: CAR-T cells targeting CD70 for renal cell cancer – promising results of a phase I COBALT-RCC study (AACR2024)
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 8, 2024, 16:13 | Insight
Piotr Wysocki: Incorporation of MRI into prostate cancer screening decreases the risk of overdiagnosis and minimizes the burden of unnecessary systemic biopsies
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 8, 2024, 14:54 | Insight
Piotr Wysocki: New data solidify the idea of omitting axillary dissection in breast cancer patients with clinically N0 disease and macrometastases in 1-2 sentinel LN
Piotr Wysocki, Head of the Clinical Oncology Department at Jagiellonian University Hospital, shared on LinkedIn:…
Apr 5, 2024, 08:40 | Insight
Piotr Wysocki: Vaccination of adult cancer patients - ASCO guidelines
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 5, 2024, 08:29 | Drugs
Piotr Wysocki: Promising activity of maintenance olaparib in advanced breast cancer patients responding to platinum-based chemotherapy
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 29, 2024, 19:49 | Insight
Piotr Wysocki: There is still no proof that proton beam therapy is superior to IMRT in terms of quality of life in patients with localized prostate cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital…
Mar 27, 2024, 10:07 | Insight
Piotr Wysocki: No benefit of continuing CDK4/6i beyond progression in advanced ER+/HER2- breast cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 25, 2024, 16:15 | Insight
Piotr Wysocki: Stereotactic ablative body radiotherapy of primary tumor is highly active in patients with localized renal cell cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 23, 2024, 04:35 | Insight
Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?
Piotr Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital, recently…
Dec 12, 2023, 17:44 | Insight
Piotr Wysocki: SABCS2023 - Adjuvant chemoimmunotherapy does not benefit TNBC patients
Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn: "SABCS2023…
Dec 11, 2023, 18:39 | Insight
Piotr Wysocki: Breast cancer patients may safely use vaginal estrogens
Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn: "Breast…
Nov 15, 2023, 19:26 | Dialogues
OncoDaily Dialogues #2 - Piotr Wysocki / Hosted by Roupen Odabashian
We continue our series of “OncoDaily Dialogues”. This initiative by OncoDaily is designed to spotlight…
All: 74 Posts: 1 - 100